Patents Examined by Jacqueline M. Stone
  • Treatment of AIDS-type disease
    Patent number: 4921837
    Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with a colony stimulating factor alone or together with erythropoietin, and/or an anti-viral agent and/or IL-2.
    Type: Grant
    Filed: July 24, 1987
    Date of Patent: May 1, 1990
    Assignee: Genetics Institute Inc.
    Inventor: Robert E. Donahue
  • Method for producing ossein hydroxyapatite compound
    Patent number: 4919931
    Abstract: A method for producing an ossein hydroxyapatite compound from bones or fetal and young animals is described. The compound so produced stimulates chondrocytes and osteoblasts and is useful in the treatment of osteoarthritis, osteoporosis, bone and cartilage defects, and in the healing of bone fractures.
    Type: Grant
    Filed: February 5, 1987
    Date of Patent: April 24, 1990
    Assignee: Robapharm AG
    Inventor: Thea Rosenberg nee Goldner
  • Composition having evaporative oil-like material
    Patent number: 4917891
    Abstract: A composition absent animal, vegetable and mineral oils, which composition has an oil and water emulsion which includes a volatile oil-like material which evaporates while on a wearer after a period of time. The emulsion also includes basically deionized water and emulsifiers. Further, the composition includes additives such as stabilizers, oil absorbers, modifiers, dispersants, humectants and preservatives. The composition can be changed to be a make-up, therapeutic or enhanced moisture lotion composition.
    Type: Grant
    Filed: April 1, 1987
    Date of Patent: April 17, 1990
    Assignee: Revlon, Inc.
    Inventors: Peter J. Kaufmann, Charles G. Friedman
  • Process for the preparation of the C1 inactivator
    Patent number: 4915945
    Abstract: The invention relates to a process for the preparation of C1 inactivator, which, if appropriate, is hepatitis-free and, if appropriate, can be lyophilized, and its use as a medicament.
    Type: Grant
    Filed: April 18, 1985
    Date of Patent: April 10, 1990
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hermann Pelzer, Helmut Heber, Norbert Heimburger, Hans M. Preis, Horst Naumann
  • Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body
    Patent number: 4914084
    Abstract: A liquid coacervate composition and a method of introducing heme, hemoproteins and/or heme-hemoprotein complexes into the body. The liquid composition, comprising an oxygen-carrying molecule containing iron and a two-phase aqueous coacervate system, can be administered orally or intraveneously. The liquid composition is utilized to augment the oxygen transport capability of the body, to treat for several of the anemias and/or to act as an oxygen-carrying plasma volume extender.
    Type: Grant
    Filed: March 26, 1987
    Date of Patent: April 3, 1990
    Assignee: Synthetic Blood Corporation
    Inventor: Bernard Ecanow
  • Purified equine immunologlobulins and method of use thereof
    Patent number: 4911910
    Abstract: Equine immunoglobulins are recovered from the pass-through fraction of a QAE column loaded with equine serum in an acidic buffer. The recovered antibodies are electrophoretically free of non-immunoglobulin proteins, including transferrin, and are recovered in a higher yield than with known methods. The purified immunoglobulins may be used to treat failure of passive transfer of maternal immunity to foals.
    Type: Grant
    Filed: November 25, 1986
    Date of Patent: March 27, 1990
    Assignee: Biotech Research Labs, Inc.
    Inventor: Raymond E. Mifflin
  • Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them
    Patent number: 4908206
    Abstract: From organs of embryonic mammalia a new extract of active ingredients is recovered which extract can be used for controlling a reduced blood flow through periperhic organs and through the brain and which extract can be also used for controlling acne vulgaris. The corresponding extracts are used as active ingredients of corresponding pharmaceutical preparations.The new pharmaceutically active extract is prepared according to a process in which polar substances having a molecular weight below 5000 are isolated from the embryonic mammalian organs avoiding any degradation of substances having a higher molecular weight. The finely divided embryonic mammalian organs are extracted with a mixture of water and a water soluble organic solvent which contains nor more than 30 vol.-% of water at an about neutral pH value for stirring and refluxing.
    Type: Grant
    Filed: September 10, 1987
    Date of Patent: March 13, 1990
    Assignee: Amics AG
    Inventors: Rolf Schafer, Hans Hitz
  • Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock
    Patent number: 4908350
    Abstract: A physiologically acceptable solution which is both hyperosmotic and hyperoncotic with respect to blood plasma and has utility in treating patients experiencing or threatening to experience hypodynamic shock. The physiologically acceptable solution comprises a hyperosmotic concentration of a crystalloid (in excess of about 1800 mOsms) and hyperoncotic concentration of a colloid (in excess of about 30 mm Hg). The physiologically acceptable solution is easily administered by single, rapid infusion of approximately 4 to 5 ml/kg of body weight and results in a rapid and sustained normalization of circulatory function.
    Type: Grant
    Filed: February 24, 1988
    Date of Patent: March 13, 1990
    Assignee: The Regents of the University of California
    Inventors: George C. Kramer, James W. Holcroft
  • Therapeutic agents for enzymatic wound cleaning
    Patent number: 4904469
    Abstract: The invention relates to a wound covering made from a polysaccharide base, particularly cellulose, which is formed as a fabric, which has a high absorbency due to its sponge-like structure and contains non-immobilized enzymes for wound therapy.
    Type: Grant
    Filed: February 5, 1987
    Date of Patent: February 27, 1990
    Assignee: Rohm GmbH Chemische Fabrik
    Inventors: Hans-Ulrich Petereit, Gerhard Zeiss
  • Preparation which promotes the absorption of peptides
    Patent number: 4900730
    Abstract: Medicinal compositions containing a water soluble absorption promoter having chelating activity, preferably in the presence of a salt at a concentration exhibiting higher osmotic pressure than isotonic sodium chloride solution, to promote absorption of the medicine through a gastrointestinal organ such as colon or rectum, and through the vagina.
    Type: Grant
    Filed: June 18, 1987
    Date of Patent: February 13, 1990
    Assignee: Toyo Jozo Co., Ltd.
    Inventor: Yasuyo Miyauchi
  • Liver lactogenic factor
    Patent number: 4895833
    Abstract: The present invention relates to liver lactogenic factor and to its isolation, purification and characterization. The liver lactogenic factor of the present invention is useful to increase mil and/or casein production in lactating female mammals. The invention additionally pertains to a novel bioassay capable of identifying lactogenic factors.
    Type: Grant
    Filed: March 6, 1987
    Date of Patent: January 23, 1990
    Assignee: The Medical University of South Carolina
    Inventor: L. Stephen Frawley
  • Methods and compositions for stimulation of appetite
    Patent number: 4891357
    Abstract: A method and composition for the stimulation of appetite in human or non-human vertebrate animals comprising the administration to the brain to the animal, an effective appetite stimulating amount of NPY or a pharmaceutically acceptable derivative, analog, salt or complex thereof.
    Type: Grant
    Filed: January 6, 1987
    Date of Patent: January 2, 1990
    Assignee: University of Florida
    Inventor: Satya P. Kalra
  • Method for the purification of LPF-HA
    Patent number: 4885359
    Abstract: Improved method for the purification of LPF-HA (Leucocytosis promoting far hemagglutinin) on industrial scale which comprises contacting a LPF-HA-containing solution from culture media of Bordetella pertussis with a cellulose sulfate gel, a crosslinked polysaccharide sulfate gel, or a polysaccharide gel chemically bound with dextran sulfate, thereby adsorbing LPF-HA on the gel, and then eluting LPF-HA from the gel. Said method can give a highly purified LPF-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.
    Type: Grant
    Filed: November 16, 1987
    Date of Patent: December 5, 1989
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Akihiro Ginnaga, Tsukasa Nishihara, Tetsuo Kawahara, Sadao Susumi, Hiroshi Mizokami, Mitsuo Sakoh
  • Method for decreasing tumor metastasis
    Patent number: 4882318
    Abstract: The invention relates to pharmaceutical compositions intended to decrease the incidence of tumor metastasis in patients who suffer from malignant diseases.The pharmaceutical compositions of the invention contain as active ingredient heparin or a suitable derivative thereof. Amongst suitable derivatives are N-desulfated and N-acetylated heparin.The dosage of the administered heparin or heparin derivative is quite critical and will generally be in the range of from 0.05 mg/kg/day to about 0.5 mg/kg/day. A preferred range is between about 0.1 mg/kg/day to about 0.5 mg/kg/day.
    Type: Grant
    Filed: June 24, 1987
    Date of Patent: November 21, 1989
    Assignees: Hadassa Medical Organization, Yeda Research and Development Company Limited
    Inventors: Israel Vlodavsky, Amiram Eldor, Yaakov Naparstek, Irun R. Cohen
  • Prostaglandin biosynthesis inhibitors
    Patent number: 4880742
    Abstract: A method of treatment of the diseases caused by AIDS virus which comprises administering an effective amount of prostaglandin biosynthesis inhibitor to a subject in need of such treatment.
    Type: Grant
    Filed: February 3, 1987
    Date of Patent: November 14, 1989
    Assignees: Research Development Corporation of Japan, Ueno Seiyaku Kabushikikaisha
    Inventors: Osamu Hayaishi, Ryuji Ueno, Sachiko Kuno
  • Method and composition for preventing the adsorption of a medicine
    Patent number: 4879272
    Abstract: A method of preventing erythropoietin in an aqueous solution from being adsorbed on the inner surface of the wall of a container by incorporating in the aqueous solution one or more additives, and an erythropoietin composition so formulated as to avoid the adsorption of erythropoietin onto the inner surface of the wall of a container are disclosed.The additives which are useful in this invention include human serum albumin, bovine serum albumin, lecithin, dextrans, ethylene oxide-propylene oxide copolymers, hydroxypropyl cellulose, methylcellulose, polyoxyethylene hydrogenated castor oils, polyethylene glycols and the like.
    Type: Grant
    Filed: October 4, 1985
    Date of Patent: November 7, 1989
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Naoto Shimoda, Tsutomu Kawaguchi
  • Pharmaceutical plasma protein formulations in low ionic strength media
    Patent number: 4877608
    Abstract: Stable factor VIII and other plasma protein formulations are provided in low ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; lysine hydrochloride; and histidine as the buffering agent.
    Type: Grant
    Filed: November 9, 1987
    Date of Patent: October 31, 1989
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Ted C. K. Lee, Michael E. Hrinda
  • Pharamaceutical composition containing ubidecarenone
    Patent number: 4869900
    Abstract: A pharmaceutical composition, comprising: Coenzyme Q.sub.10 (ubidecarenone) 2-17% by weight; Lecithin 50-70% by weight; Surfactant agent 20-48% by weight. The surfactant agent has a melting point comprised between 35.degree. and 55.degree. C. and a HLB value from 12 to 15. Said composition provides a high absorption of Coenzime Q.sub.10. Solid pharmaceutical preparations containing the above composition are described too.
    Type: Grant
    Filed: November 6, 1986
    Date of Patent: September 26, 1989
    Assignee: Zambon S.p.A.
    Inventors: Franco Pozzi, Antonio Longo, Angelo Carenzi
  • Stimulation of tear secretion with melanocyte stimulating hormones
    Patent number: 4868154
    Abstract: A method and preparation for the stimulation of tear secretion. The method involves topically applying to the ocular surface melanocyte stimulating hormones, and their active precursors, derivatives, and fragments which activate melanotropin receptors of lacrimal gland tissue. The preparation contains a melanocyte stimulating hormone, and a vehicle for a melanocyte stimulating hormone and may also contain an ophthalmic preservative.
    Type: Grant
    Filed: February 19, 1986
    Date of Patent: September 19, 1989
    Assignee: Eye Research Institute of Retina Foundation
    Inventors: Jeffrey P. Gilbard, Darlene A. Dartt
  • Platinum bound to transferrin for use in the treatment of breast tumors
    Patent number: RE33071
    Abstract: A method of preparing an anti-breast tumor compound comprised of a toxic metal bound to the blood protein transferrin is disclosed which has superior therapeutic properties. When monomeric transferrin is bound to cis-Dichlorodiammineplatinum (II), a chemotherapeutic agent is produced which specifically attacks and kills rapidly multiplying breast tumor cells without damaging normal cells. In addition, the body's immune defenses against foreign substances are substantially not activated. In preferred embodiments, 1.8-2.2 atoms of platinum are bound to each molecule of transferrin. The platinum-transferrin is prepared by first protecting the sulfhydro groups on essentially iron free transferrin with an excess of cystine in solution. Cis-dichlorodiamine platinum (II) is then reacted with the iron-free transferrin in the presence of bicarbonate anion.
    Type: Grant
    Filed: January 4, 1988
    Date of Patent: September 26, 1989
    Inventor: Rune L. Stjernholm